Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-cash Items (2016 - 2023)

Historic Non-cash Items for Theravance Biopharma (TBPH) over the last 9 years, with Q4 2023 value amounting to $859000.0.

  • Theravance Biopharma's Non-cash Items rose 1083.87% to $859000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $859000.0, marking a year-over-year increase of 1083.87%. This contributed to the annual value of $859000.0 for FY2023, which is 1083.87% up from last year.
  • Per Theravance Biopharma's latest filing, its Non-cash Items stood at $859000.0 for Q4 2023, which was up 1083.87% from $775000.0 recorded in Q4 2022.
  • Theravance Biopharma's 5-year Non-cash Items high stood at $8.5 million for Q4 2019, and its period low was $775000.0 during Q4 2022.
  • In the last 5 years, Theravance Biopharma's Non-cash Items had a median value of $1.1 million in 2021 and averaged $2.5 million.
  • As far as peak fluctuations go, Theravance Biopharma's Non-cash Items skyrocketed by 6666.67% in 2019, and later crashed by 8588.24% in 2020.
  • Quarter analysis of 5 years shows Theravance Biopharma's Non-cash Items stood at $8.5 million in 2019, then crashed by 85.88% to $1.2 million in 2020, then dropped by 10.83% to $1.1 million in 2021, then decreased by 27.57% to $775000.0 in 2022, then grew by 10.84% to $859000.0 in 2023.
  • Its Non-cash Items was $859000.0 in Q4 2023, compared to $775000.0 in Q4 2022 and $1.1 million in Q4 2021.